A prospective study found that PSMA PET/CT-guided targeted biopsy detects clinically significant prostate cancer in 37% of men with negative or inconclusive MRI—nearly doubling detection when combined with systematic biopsy. The data reinforce PSMA imaging’s role as a triage tool to reduce missed clinically important lesions in patients who otherwise qualify for fewer invasive steps.